Stock A156100 L&K BIOMED LTD.
Add to a list
To use this feature you must be a member
Log inSign up

Ratings L&K Biomed Ltd.

Equities

A156100

KR7156100000

End-of-day quote Korea S.E.
Other stock markets
 03:30:00 31/05/2024 am IST 		5-day change 1st Jan Change
9,980 KRW -2.16% Intraday chart for L&K Biomed Ltd. +7.43% -1.96%
09/05 L&K Biomed Ltd. announced that it has received KRW 20 billion in funding from a group of investors CI
07/05 L&K Biomed Ltd. announced that it expects to receive KRW 20 billion in funding from a group of investors CI

Summary

  • The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.

Strengths

  • The prospective high growth for the next fiscal years is among the main assets of the company

Weaknesses

  • In relation to the value of its tangible assets, the company's valuation appears relatively high.
  • The group usually releases earnings worse than estimated.

Ratings chart - Surperformance

Sector: Medical Equipment, Supplies & Distribution

1st Jan change Capi. Investor Rating ESG Refinitiv
L&K BIOMED LTD. Stock L&K Biomed Ltd.
-1.96% 144M -
STRYKER CORPORATION Stock Stryker Corporation
+13.73% 130B
A-
SMITH & NEPHEW PLC Stock Smith & Nephew Plc
-8.17% 10.99B
A-
IMEIK TECHNOLOGY DEVELOPMENT CO.,LTD. Stock Imeik Technology Development Co.,Ltd.
-4.33% 8.35B
C
GLAUKOS CORPORATION Stock Glaukos Corporation
+41.80% 5.67B
B+
INSPIRE MEDICAL SYSTEMS, INC. Stock Inspire Medical Systems, Inc.
-21.94% 4.72B
C
AXONICS, INC. Stock Axonics, Inc.
+7.81% 3.42B
C-
ENOVIS CORPORATION Stock Enovis Corporation
-10.26% 2.76B
B-
BEIJING BALANCE MEDICAL TECHNOLOGY CO.,LTD. Stock Beijing Balance Medical Technology Co.,Ltd.
-10.29% 2.11B - -
SHANGHAI MICROPORT ENDOVASCULAR MEDTECH CO., LTD. Stock Shanghai MicroPort Endovascular MedTech Co., Ltd.
-13.58% 1.92B -
Investor Rating
Trading Rating
ESG Refinitiv
-

Financials

Sales growth
Earnings Growth
-
EBITDA / Sales
Profitability
Finances

Valuation

P/E ratio
EV / Sales
Price to Book
Price to Free Cash Flow
Yield
-

Momentum

1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
4 months EPS revision

Consensus

Analyst Opinion
Potential Price Target
-
4m Target Price Revision
-
4m Revision of opinion
-
12m Revision of opinion
-

Business Predictability

Analyst Coverage
Divergence of Estimates
-
Divergence of analysts' opinions
-
Divergence of Target Price
-
Earnings quality
  1. Stock Market
  2. Equities
  3. A156100 Stock
  4. Ratings L&K Biomed Ltd.